Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade ; volume:43 ; number:1 ; day:16 ; month:3 ; year:2024 ; pages:1-22 ; date:12.2024
Journal of experimental & clinical cancer research ; 43, Heft 1 (16.3.2024), 1-22, 12.2024
- Urheber
-
Tsai, Yo-Ting
Schlom, Jeffrey
Donahue, Renee N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-024-02969-1
- URN
-
urn:nbn:de:101:1-2405210728578.524585218822
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsai, Yo-Ting
- Schlom, Jeffrey
- Donahue, Renee N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer
Prospects for combining immune checkpoint blockade with PARP inhibition
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
An unsuspected complication with immune checkpoint blockade: a case report
Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
Systemic effects of combination of ablative hypofractionated radiotherapy with immune checkpoint blockade
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer
Prospects for combining immune checkpoint blockade with PARP inhibition
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
An unsuspected complication with immune checkpoint blockade: a case report
Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
Systemic effects of combination of ablative hypofractionated radiotherapy with immune checkpoint blockade
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer
Prospects for combining immune checkpoint blockade with PARP inhibition
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
An unsuspected complication with immune checkpoint blockade: a case report
Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade